The role of PTEN and TP53 co-mutations in immunotherapy of lung cancer.

被引：0
|
作者：
Ma, Xiaolong
Zhang, Ding
Chen, Shiqing
机构：
[1] First Hosp Jiaxing, Dept Resp Med, Jiaxing, Peoples R China
[2] 3D Med Inc, Med Dept, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.e21161
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21161
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Targeting the Chemoradiation Resistance of Lung Cancers with KRAS/TP53 Co-Mutations
    Willers, H.
    Gurtner, K.
    Benes, C.
    Baumann, M.
    Krause, M.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (11) : S1138 - S1139
  • [2] KEAP1 and TP53 Mutations in Lung Cancer: More Is Better. Reply to: "Survival Analysis of TP53 Co-Mutations Should Be Interpreted More Cautiously"
    Scalera, Stefano
    Mazzotta, Marco
    Cappuzzo, Federico
    Ciliberto, Gennaro
    Maugeri-Sacca, Marcello
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (03) : E40 - E41
  • [3] A Pan-Cancer Assessment of RB1/TP53 Co-Mutations
    Cai, Ling
    DeBerardinis, Ralph J.
    Xiao, Guanghua
    Minna, John D.
    Xie, Yang
    [J]. CANCERS, 2022, 14 (17)
  • [4] The impact of TP53 co-mutations and immunologic microenvironment on outcome of lung cancer with EGFR exon 20 insertions
    Christopoulos, Petros
    Kluck, Klaus
    Kirchner, Martina
    Lueders, Heike
    Roeper, Julia
    Falkenstern-Ge, Roger-Fei
    Szewczyk, Marlen
    Sticht, Florian
    Saalfeld, Felix C.
    Wesseler, Claas
    Hackanson, Bjoern
    Dintner, Sebastian
    Faehling, Martin
    Kuon, Jonas
    Janning, Melanie
    Kauffmann-Guerrero, Diego
    Kazdal, Daniel
    Kurz, Sylke
    Eichhorn, Florian
    Bozorgmehr, Farastuk
    Shah, Rajiv
    Tufman, Amanda
    Wermke, Martin
    Loges, Sonja
    Brueckl, Wolfgang M.
    Schulz, Christian
    Misch, Daniel
    Frost, Nikolaj
    Kollmeier, Jens
    Reck, Martin
    Griesinger, Frank
    Grohe, Christian
    Hong, Jin-Liern
    Lin, Huamao M.
    Budczies, Jan
    Stenzinger, Albrecht
    Thomas, Michael
    [J]. EUROPEAN JOURNAL OF CANCER, 2022, 170 : 106 - 118
  • [5] Stability of rare TP53 co-mutations in AML patients.
    Bloom, Kenneth Joel
    Idica, Adam
    Smart, Dave
    Allen, Wendy
    Scanlon, Enya
    Clark, Jordan
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [6] Relations between mutant KRAS and TP53 subtypes and other co-mutations in pancreatic cancer
    Abraham, Soniya
    Zhang, Janie Yue
    Walther, Zenta
    Parekh, Jay
    Lacy, Jill
    Cecchini, Michael
    Hu, Yiduo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [7] Cigarette smoking and TP53 mutations in bladder cancer.
    Zhang, ZF
    Lu, ML
    Cordon-Cardo, C
    Shu, XM
    Cao, PQ
    Connolly-Jenks, C
    Dalbagni, G
    Reuter, VE
    Scher, H
    [J]. AMERICAN JOURNAL OF EPIDEMIOLOGY, 1999, 149 (11) : S66 - S66
  • [8] Kras Co-mutations lead to resistance to mutant TP53 targeted therapy in mouse models of spontaneous non-small cell lung cancer.
    Costa, David T.
    Grier, Shaylyn
    Perez, Melanie
    Gao, Li
    Villalona-Calero, Miguel A.
    Duan, Wenrui
    [J]. CANCER RESEARCH, 2022, 82 (12)
  • [9] Association between microsatellite instability and BRAF, TP53, PTEN, and KRAS mutations in colorectal cancer.
    Albitar, Maher
    Sudarsanam, Sucha
    Ma, Wanlong
    Jiang, Shiping
    Chen, Wayne
    Funari, Vincent Anthony
    Blocker, Forrest
    Agersborg, Sally
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [10] Frequency and patterns of TP53 mutations in lung cancer
    Yang, Yaxian
    Wang, Heran
    Wang, Lucas
    Fan, WenTao
    Lian, Bin
    Jin, Ying
    Luo, Weiquan
    Mao, Jiewei
    Feng, Yilin
    Xie, Hongtao
    Huang, Mingjian
    Zheng, Liyu
    Pan, Zhaodong
    Huang, Mingming
    Wang, Yongsi
    Wen, Yunjie
    Huang, Jian
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345